The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 16 rounds in the feed, most often in Biotech.
Venture capitalcataliocapital.comRounds from 2022-10-13 to 2026-10-22
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Funding round Verified against 1 of 9 sources | $200M | 2026-10-22 | [ PART ] |
ZAP Surgical Systems A global leader in non-invasive robotic brain surgery | Funding round Verified against 1 of |
| $36M |
| 2026-10-19 |
| [ LEAD ] |
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series E Verified against 4 of 37 sources | $311M | 2026-09-23 | [ LEAD ] |
BigHat Biosciences A clinical-stage, AI-driven protein therapeutics platform company | Series C Verified against 4 of 28 sources | $75M | 2026-09-23 | [ PART ] |
Basecamp Research A London AI company that trains frontier models on its proprietary Trillion Gene Atlas to design therapeutics, starting with in vivo cell therapies | Series C Verified against 4 of 62 sources | $140M | 2026-09-23 | [ PART ] |
Evvy Evvy sells an at-home vaginal microbiome test and a clinical care platform that treats the conditions it finds. | Series B Verified against 1 of 14 sources | $40M | 2026-09-15 | [ LEAD ] |
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
Imperative Care Medical devices and technologies for treating strokes and vascular diseases. | Convertible Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-03-19 | [ PART ] |
Hippocratic AI Hippocratic AI offers generative AI solutions to improve communication and care delivery in healthcare settings, selling primarily to healthcare providers, payors, and pharmaceutical companies. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $126M | 2025-11-03 | [ PART ] |
LILA Sciences Advanced AI solutions for scientific research and experimentation. | Series A ext. Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-10-10 | [ PART ] |
Leo Cancer Care Leo Cancer Care makes upright radiation therapy systems that treat cancer patients seated or standing. | Funding round Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2025-09-24 | [ LEAD ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |
GlycoEra Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-27 | [ PART ] |
Imperative Care Medical devices and technologies for treating strokes and vascular diseases. | Series D+ Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | up to $150M financing total | 2024-07-25 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-09-27 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |